Treatment of Severe Osteoporosis

Defining Very High Risk

• The American College of Physicians recommends that very high risk for fracture includes patients with age >74 years, multiple prior osteoporotic fractures, T-score ≤-3.0, and high FRAX scores (≥20% for major osteoporotic fracture or ≥3% for hip fracture) 1, 2, 3

First-Line Treatment for Severe Osteoporosis

• The American College of Internal Medicine recommends initiating treatment with anabolic agents (romosozumab or teriparatide) followed by mandatory transition to bisphosphonates or denosumab to maintain bone gains for patients with severe osteoporosis at very high risk of fracture 4, 1
• Romosozumab is conditionally recommended for very high-risk postmenopausal women with low-certainty evidence 1
• Teriparatide reduces vertebral fractures by 69 per 1000 patients and any clinical fractures by 27 per 1000 patients 1

Alternative Treatment Pathway

• Bisphosphonates remain first-line for most patients even with severe osteoporosis if very high-risk criteria are not met, with high-certainty evidence for reducing hip and vertebral fractures 4, 1, 5
• Oral bisphosphonates, such as alendronate and risedronate, are preferred, with generic formulations strongly recommended due to significantly lower cost with equivalent efficacy 1

Second-Line Treatment

• Denosumab is reserved for patients with contraindications to bisphosphonates or who experience adverse effects, with moderate-certainty evidence for postmenopausal women and low-certainty evidence for men 4, 1, 5, 6

Essential Adjunctive Measures

• All patients require calcium (1000-1200 mg daily), vitamin D (800-1000 IU daily), weight-bearing and muscle resistance exercises, balance exercises, fall prevention counseling, smoking cessation, and alcohol reduction 4, 1, 2, 3, 6

Treatment Algorithm for Severe Osteoporosis

• The treatment algorithm involves confirming diagnosis, assessing for very high-risk features, starting anabolic agent or bisphosphonate, and mandatory transition to bisphosphonate or denosumab after anabolic therapy completion 4, 1

Anabolic Bone Pharmacologic Treatment Recommendation

Rationale for Anabolic Therapy Selection

• The American College of Physicians recommends that patients with very high fracture risk, such as those with multiple prior osteoporotic fractures and severe osteoporosis, should be treated with anabolic therapy rather than antiresorptive agents, with teriparatide being the preferred anabolic agent for its superior non-vertebral fracture reduction, established efficacy in elderly patients, and rapid increases in bone formation markers 7, 8

Treatment Protocol

• The treatment protocol for teriparatide involves a daily subcutaneous injection of 20 mcg for 18-24 months, with expected outcomes including a 10% increase in spine BMD, 3% increase in hip BMD, and significant fracture risk reduction, after which patients must transition to an antiresorptive agent to maintain bone gains and prevent rebound fractures 7, 8

Contraindications to Verify

• Before prescribing teriparatide, it is essential to confirm the absence of contraindications such as Paget's disease of bone, prior skeletal radiation therapy, bone metastases or history of skeletal malignancies, and active malignancies prone to bone metastases, as these conditions may increase the risk of adverse effects 7, 8

Monitoring and Safety

• The Endocrine Society recommends monitoring for hypercalcemia and urinary calcium levels during teriparatide treatment, as well as providing patient education and adherence support to ensure daily subcutaneous injections are administered correctly 7, 8

Anabolic Therapy for Osteoporosis

Patient Selection and Treatment Guidelines

• The American College of Rheumatology conditionally recommends anabolic agents, such as teriparatide, over anti-resorptives for patients at very high fracture risk, particularly those who have failed bisphosphonate therapy, as seen in elderly underweight females with severe osteoporosis and multiple fractures 9
• Elderly age and underweight status are independent risk factors for osteoporosis, making anabolic therapy a suitable option for this patient population 10
• Teriparatide is compatible with GI pathology, such as active gastric and duodenal ulcers, due to its subcutaneous administration, making it a suitable option for patients with upper GI issues 11

Treatment Protocol and Monitoring

• The American College of Rheumatology recommends calcium supplementation of 1,000-1,200 mg daily and vitamin D supplementation of 600-800 IU daily, targeting serum 25(OH)D levels ≥30-50 ng/mL, for patients on teriparatide therapy 9
• It is essential to monitor serum calcium and urinary calcium at 1 month after initiation of teriparatide and then as clinically indicated, to prevent hypercalcemia 9

Post-Treatment Care

• The American College of Rheumatology guidelines emphasize the importance of transitioning to anti-resorptive therapy, such as denosumab, immediately after completing teriparatide, to maintain bone gains and prevent rebound fractures, especially in patients with active GI ulcers 11
• Denosumab is a preferred sequential agent due to its avoidance of upper GI exposure, making it suitable for patients with active GI ulcers 11

Fracture Prevention with Bisphosphonates

Introduction to Bisphosphonate Therapy

• The American Geriatrics Society recommends that bisphosphonate treatment requires 3-18 months before fracture risk reduction becomes evident, with benefits beginning after 9-12 months of treatment 12

Treatment Decision Algorithm

• For patients with recent vertebral fracture, the European League Against Rheumatism suggests starting alendronate 70 mg weekly as first-line therapy, which reduces vertebral fractures by 45% in secondary prevention with 6% absolute risk reduction 13, 14
• The American College of Rheumatology recommends essential concurrent measures, including calcium 1000-1200 mg daily, vitamin D 800-1000 IU daily, fall prevention strategies, and weight-bearing exercise when medically appropriate 13

Critical Timing Considerations

• The American Geriatrics Society notes that secondary fracture risk is highest in the first year after initial fracture, and delaying treatment increases risk of additional fractures 13
• The American College of Rheumatology recommends starting treatment immediately, as the 9-12 month lag before fracture benefit means starting immediately is essential 12

Administration Requirements

• The American Geriatrics Society recommends taking alendronate with a full glass of plain water (6-8 ounces) after overnight fast, remaining upright for at least 30 minutes, and avoiding food, drink, or other medications during this period 12

Common Pitfall to Avoid

• The American College of Physicians recommends explaining to patients that treatment prevents the next fracture, which is critically important given their 6% absolute risk of another vertebral fracture over 3 years without treatment 14